A Phase Iii Randomized Trial Of Pleurectomy/Decortication Plus Chemotherapy With Or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (Imprint) For Malignant Pleural Mesothelioma (Mpm) (Nrg-Lu006)

TBD CONCLUSION: NRG LU-006 is now open to accrual. This is the first NRG Oncology randomized phase III trial on malignant pleural mesothelioma and evaluates the use of IMPRINT following lung-sparing P/D and chemotherapy. Treatment planning aspects and current status will be presented.